Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1109073

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hyperkalaemia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the prevalence of hyperkalaemia for patients with chronic kidney disease.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	239857
	answer	answer is ministerial correction date of answer 08/04/2019 answer text <p>Hyperkalaemia usually occurs in patients with renal impairment which can be acute or chronic. In patients with chronic kidney disease (CKD), several factors increase susceptibility to hyperkalaemia including a high dietary potassium intake relative to residual renal function. When patients with CKD have other risk factors, for example treatment with drugs that interfere with the renin-angiotensin-aldosterone system, the risk of hyperkalaemia is further increased. Clinical presentation of hyperkalaemia is highly variable with some patients presenting with an acute illness whilst others may be asymptomatic.</p><p> </p><p>Although not completely preventable, the risk of developing hyperkalaemia can be reduced. Clinical practice guidelines treatment of acute hyperkalaemia in adults, a collaboration between the Renal Association and Resuscitation Council UK that is endorsed by a range of organisations, including the College of Emergency Medicine and the Faculty of Intensive Care medicine, sets out evidence-based guidance on the management of the condition. It was developed to improve the treatment of acute hyperkalaemia and to reduce the risk of complications associated with hyperkalaemia and its treatment. The main measures in primary prevention in patients with CKD are regular blood monitoring, careful drug prescribing and dietary advice. Patient information and education may reduce the risk of inadvertent hyperkalaemia. The guidance can be found at the following link:</p><p> </p><p><a href="https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf" target="_blank">https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf</a></p><p> </p><p>Information regarding the annual cost to the National Health Service of treating hyperkalaemia in Coventry South and England is not available. This answer covers England only. Funding of such services in the other United Kingdom nations is a matter for the respective devolved administrations.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 239865 question first answered 08/04/2019 15:20:04 answering member 4455 label Biography information for Seema Kennedy
	tabling member	308 label Biography information for Mr Jim Cunningham

1109260

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hyperkalaemia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the annual cost to the NHS of treating hyperkalaemia in (a) Coventry South constituency and (b) the UK.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	239865
	answer	answer is ministerial correction date of answer 08/04/2019 answer text <p>Hyperkalaemia usually occurs in patients with renal impairment which can be acute or chronic. In patients with chronic kidney disease (CKD), several factors increase susceptibility to hyperkalaemia including a high dietary potassium intake relative to residual renal function. When patients with CKD have other risk factors, for example treatment with drugs that interfere with the renin-angiotensin-aldosterone system, the risk of hyperkalaemia is further increased. Clinical presentation of hyperkalaemia is highly variable with some patients presenting with an acute illness whilst others may be asymptomatic.</p><p> </p><p>Although not completely preventable, the risk of developing hyperkalaemia can be reduced. Clinical practice guidelines treatment of acute hyperkalaemia in adults, a collaboration between the Renal Association and Resuscitation Council UK that is endorsed by a range of organisations, including the College of Emergency Medicine and the Faculty of Intensive Care medicine, sets out evidence-based guidance on the management of the condition. It was developed to improve the treatment of acute hyperkalaemia and to reduce the risk of complications associated with hyperkalaemia and its treatment. The main measures in primary prevention in patients with CKD are regular blood monitoring, careful drug prescribing and dietary advice. Patient information and education may reduce the risk of inadvertent hyperkalaemia. The guidance can be found at the following link:</p><p> </p><p><a href="https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf" target="_blank">https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf</a></p><p> </p><p>Information regarding the annual cost to the National Health Service of treating hyperkalaemia in Coventry South and England is not available. This answer covers England only. Funding of such services in the other United Kingdom nations is a matter for the respective devolved administrations.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 239857 question first answered 08/04/2019 15:20:04 answering member 4455 label Biography information for Seema Kennedy
	tabling member	308 label Biography information for Mr Jim Cunningham

1109333

	registered interest
	date	03/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the saving to the NHS of reducing the number of prescriptions for over-the-counter medicines.
	tabling member constituency	Rother Valley
	tabling member printed	Sir Kevin Barron
	uin	240507
	answer	answer is ministerial correction date of answer 08/04/2019 answer text <p>The Department has made no such assessment. From December 2017 to March 2018, NHS England carried out a public consultation on reducing prescribing of over-the-counter medicines for minor, short-term health concerns, ‘Conditions for which over the counter items should not routinely be prescribed in primary care: A consultation on guidance for CCGs’ which can be found at the following link:</p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/over-the-counter-items-not-routinely-prescribed/" target="_blank">https://www.engage.england.nhs.uk/consultation/over-the-counter-items-not-routinely-prescribed/</a></p><p> </p><p>At the end of March 2018, NHS England published guidance to enable savings of up to £100 million for frontline care each year by curbing prescriptions for ‘over the counter’ medicines. The guidance does not affect prescribing of over the counter items for longer term or more complex conditions, or where minor illnesses are symptomatic or a side effect of something more serious.</p><p> </p><p>We are informed by NHS England that in the 12 months to January 2019, the total National Health Service spend in England on over the counter items was £449.4 million. This was a saving on total spend of £25.9 million from the corresponding figure for the 12 months to January 2018, which was £475.3 million. This saving does not account for the potential impact to the NHS from a reduced number of general practitioner appointments, for which no assessment has been made.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 08/04/2019 15:21:59 answering member 4455 label Biography information for Seema Kennedy
	tabling member	392 label Biography information for Sir Kevin Barron